EurekaMag.com logo
+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The effect of the nonpeptide AII antagonist losartan on systemic blood pressure and renal and extrarenal prostaglandin production in women with essential hypertension



The effect of the nonpeptide AII antagonist losartan on systemic blood pressure and renal and extrarenal prostaglandin production in women with essential hypertension



Journal of the American Society of Nephrology 4(3): 540




(PDF emailed within 1 workday: $29.90)

Accession: 033785723

Download citation: RISBibTeXText



Related references

The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension. American Journal of Hypertension 8(12 PART 1): 1177-1183, 1995

Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. American Journal of Hypertension 6(1): 28-32, 1993

Blood pressure normalization restores normal renal prostaglandin production in essential hypertension. Contributions to Nephrology 49: 179-184, 1985

Effects of losartan on blood pressure, renin-aldosterone, and renal function in essential hypertension. Journal of the American Society of Nephrology 4(3): 529, 1993

Effects of losartan and chlorthalidone on blood pressure and renal vascular resistance index in non-diabetic patients with essential hypertension and normal renal function. Journal of Cardiovascular Pharmacology 44(5): 520-524, 2004

Effects of losartan on blood pressure, renin-angiotensin-aldosterone, and renal function in essential hypertension. Journal of Investigative Medicine 43(SUPPL 3): 423A, 1995

Apelin polymorphism predicts blood pressure response to losartan in older Chinese women with essential hypertension. Genetics and Molecular Research 14(2): 6561-6568, 2016

Experimental ischemic renal injury--effect of surgical technique and the protective effect of a nonpeptide angiotensin II antagonist (losartan). Rozhledy V Chirurgii 79(8): 385-391, 2000

The antiproteinuric effect of losartan and its relationship to systemic blood pressure and renal haemodynamics in patients with chronic renal failure. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 481A, September, 2001

Effect of Losartan, a nonpeptide angiotensin II receptor antagonist, on drinking behavior and renal actions of centrally administered renin. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine 202(4): 401-406, 1993

Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 262(3): 1168-1172, 1992

Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure. Journal of Cardiovascular Pharmacology 22(6): 785-791, 1993

Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. American Heart Journal 144(3): 530-537, 2002

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. New England Journal of Medicine 338(12): 784-790, March 19, 1998

The effect of inhibition of prostaglandin synthesis on plasma renin activity and blood pressure in essential hypertension. Prostaglandins and Medicine 1(6): 479-488, 1978